Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies.
Tumor-induced angiogenesis is essential for malignant growth. This mini review focuses on the role of vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) and their receptors in this process, and the rationale to combine inhibitors of these growth factors as anticancer therapy. Concomitantly, targeting the VEGF(R) and the EGF(R) signaling pathway may circumvent the problem of acquired resistance to EGFR inhibitors. By targeting both pathways, the antiangiogenic effect may be more pronounced, which may lead to greater antitumor activity. Preliminary efficacy data from clinical trials encourage further exploration of this combined anticancer strategy.
van Cruijsen
Hester
H
Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.
Giaccone
Giuseppe
G
Hoekman
Klaas
K
D002478:Cells, Cultured; D042783:Endothelial Cells; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000502:physiology*; D006801:Humans; D008833:Microcirculation; D009369:Neoplasms / Q000098:blood supply* / Q000628:therapy*; D009389:Neovascularization, Pathologic; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors / Q000502:physiology; D015398:Signal Transduction; D014471:Umbilical Veins
D066246:ErbB Receptors; D040262:Receptors, Vascular Endothelial Growth Factor